Robust evidence for fenofibrate in patients with metabolic syndrome on statins | Multidisciplinary

A nationwide population-based cohort study in South Korea compared the effectiveness of omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE) in individuals with metabolic syndrome (≥30 years) on statin therapy.¹

1. Kim NH, et al. Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study. Eur Heart J Cardiovasc Pharmacother 2023 Nov 28:pvad090 [Online ahead of print].

Resources

Robust evidence for fenofibrate in patients with metabolic syndrome on statins